ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center
July 23 2024 - 2:00AM
Business Wire
MSA enables collaboration on full suite of
ViroCell’s viral vector manufacturing services to accelerate the
cancer center’s clinical development of novel gene-modified cell
therapies
Agreement follows ViroCell’s successful GMP
manufacture and release of a lentivirus vector for the cancer
center’s clinical evaluation of a novel engineered TCR therapy
ViroCell Biologics (“ViroCell” or the “Company”) a cell and gene
therapy (“CGT”) contract development and manufacturing organization
(“CDMO”) specializing in GMP viral vector manufacturing for
clinical trials, announces the signing of a five-year Master
Services Agreement (“MSA”) with a prominent U.S. NCI-designated
cancer center.
Under the MSA, the cancer center will have access to ViroCell’s
full range of pre-clinical and clinical viral vector services to
accelerate its clinical development of novel gene-modified cell
therapies. Pre-clinical services available include viral vector
design, MicroBatch© and pre-clinical batch manufacturing and
process development. Clinical services include global plasmid
sourcing, GMP manufacturing, expedited quality control release
testing, regulatory filing support, and in-house Qualified Person
(QP) batch review and approval for export and use in global
clinical trials.
The signing of the MSA follows the successful GMP manufacture of
a lentivirus vector by ViroCell for use by the cancer center in the
clinical evaluation of a novel engineered T cell receptor (TCR)
therapy, for the treatment of a variety of cancers. The vector was
released to the cancer center for clinical use less than five
months after the start of GMP manufacture.
John W. Hadden II, CEO at ViroCell, commented:
“We are delighted to have signed this Master Services Agreement
with one of the world’s premier cancer research centers. It further
underscores our ability to provide highly specialised GMP viral
vector manufacturing services to cutting-edge research groups both
in academia and industry as they translate their science into
next-generation cell and gene therapies. We look forward to working
closely with the scientists at this prestigious institution, as
they commence exciting new cancer drug development programs.”
Notes to editor:
ViroCell
ViroCell Biologics is an innovation-driven Contract Development
and Manufacturing Organization (“CDMO”) focused exclusively on the
design, derisking, and GMP manufacture of viral vectors for
clinical trials. Built around one of the most prolific academic
viral vector manufacturing teams, ViroCell was created to address
the global demand for precisely engineered viral vectors and aims
to become the partner of choice for companies developing cell and
gene therapies. The team leverages its deep track record to help
clients to de-risk and accelerate novel cell and gene therapies
into and through clinical development, with a mission of being the
partner of choice for corporate and academic innovators in this
field. Focused initially on manufacturing lentivirus and
gamma-retrovirus vectors, ViroCell enables clients to start
clinical trials on a scalable platform, delivering value by
reducing costs, time and regulatory risk.
www.virocell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240722521261/en/
For more ViroCell information, please contact:
ViroCell John W. Hadden II, CEO info@virocell.com
For ViroCell media enquiries, please contact:
FTI Consulting Simon Conway / Victoria Foster Mitchell /
Tim Stamper ViroCell@fticonsulting.com +44 (0)20 3727 1000